Janux Therapeutics Financials - Benzinga

Janux Therapeutics Inc

JANXNASDAQ

Trade with Public

Trade with Public

$17.10

-0.58-3.28%

At close: Sep 11, 5:00 PM EST

$17.34

0.241.4%

After Hours: 7:45 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Janux Therapeutics Financials

Janux Therapeutics (JANX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of $(0.55) per share

Benzinga Newsdesk

PRO
Janux Therapeutics Q1 EPS $(0.39) Beats $(0.53) Estimate, Sales $3.733M Miss $3.833M Estimate

Benzinga Newsdesk

PRO
Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.64) by 20.19 percent. This is a 41.67 percent decrease over losses of $(0.36) per share

Benzinga Newsdesk

Gold Down Over 1%; Signet Shares Fall After Q3 Results

Avi Kapoor

Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings

Avi Kapoor

PRO
Janux Therapeutics Q3 EPS $(0.39) Beats $(0.60) Estimate, Sales $10.000M Beat $2.929M Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 34.67 percent. This is a 23.53 percent increase over losses of $(0.51) per share

Benzinga Newsdesk